Zantac: Sales of heartburn drug suspended by retailer over cancer fears
‘This action is being taken out of an abundance of caution,’ says CVS
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A US retailer has said it will suspend sales of popular heartburn treatment Zantac at its pharmacies over a fears it could be linked to an increased risk of cancer.
CVS Health Corp said it will also discontinue its own-brand ranitidine products, which help reduce stomach acid, until further notice.
The US Food and Drug Administration (FDA) found traces of a known carcinogen in some medicines containing the drug ranitidine, including Zantac products, in findings published earlier this month.
Walgreens and Walmart have also stopped selling Zantac.
“This action is being taken out of an abundance of caution due to a recent Product Alert from the FDA,” a CVS Health statement said, “that ranitidine products may contain a low level of nitrosodimethylamine (NDMA), which is a probable human carcinogen.”
The FDA is continuing investigations into whether low levels of NDMA in the medicines could be dangerous for patients.
“The levels that FDA is finding in ranitidine from preliminary tests barely exceed amounts found in common foods,” CVS Health Corp said.
Despite being taken of pharmacy shelves until further notice, Zantac and CVS brand ranitidine products have not been recalled by the retailer.
The FDA said it does not currently advise patients to stop taking ranitidine medicines.
If patients wish to change their ranitidine medication, however, the FDA said other drugs used for similar treatments could be available to them and suggested speaking to a healthcare professional.
Ranitidine is used to treat indigestion and heartburn by reducing the amount of acid your stomach makes.
The drug can also be taken for stomach ulcers.
All types of ranitidine are available on prescription in the UK, with the lowest strength tablets available for purchase, according to the NHS website.
A spokesperson for the UK Medicines & Healthcare products Regulatory Agency (MHRA) said: “We are not aware of any specific information that would indicate that there is any risk to patients and we are not currently initiating any product recalls.
"We are monitoring the issue, continue to liaise with our European counterparts, and will take appropriate action if necessary.”
Novartis AG’s Sandoz unit said last week it was halting distribution of Zantac in all its markets, including the US and Canada, following safety review of the drug by US and European drug regulators.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments